Bicycle therapeutics presents updated clinical results across oncology pipeline at esmo congress 2024

Barcelona--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced updated phase 1/2 clinical results for bicycle toxin conjugate (btc®) zelenectide pevedotin (formerly bt8009) in metastatic urothelial cancer (muc); btc molecule bt5528 in advanced solid tumors, such as muc and ovarian; and bicycle tumor-targeted immune cell agonist.
BCYC Ratings Summary
BCYC Quant Ranking